Dongkook Pharmaceutical Participates in 'CPHI 2025'... Expanding Global Network
Dongkook Pharmaceutical announced on the 6th that it participated in 'CPHI Worldwide 2025,' the world's largest pharmaceutical and bio industry exhibition, held in Frankfurt, Germany from October 28 to 30.
Dongkook Pharmaceutical booth participating in 'CPHI Worldwide 2025,' the world's largest pharmaceutical and bio industry exhibition held in Frankfurt, Germany. Dongkook Pharmaceutical
View original image'CPHI Worldwide' is a flagship event for the pharmaceutical and bio industry, held annually in major European countries. This year’s event brought together more than 2,400 pharmaceutical and bio companies and over 62,000 industry professionals from around 160 countries worldwide.
Dongkook Pharmaceutical operated an independent booth, focusing on promoting the technological excellence of its long-acting injectable (Depot) products, 'Lorelindepho' and 'Octrinlar,' both utilizing its proprietary Microsphere technology. The company also highlighted the superior efficacy and safety data of its improved drug for benign prostatic hyperplasia, 'Uresco Tab' (a combination of dutasteride and tadalafil), based on Phase 3 clinical trial results, emphasizing the product’s differentiation and market competitiveness to global buyers.
As a result, more than 300 existing partners and new buyers visited the Dongkook Pharmaceutical booth, and numerous new consultations regarding Uresco Tab were also conducted.
A Dongkook Pharmaceutical representative stated, "At this year’s 'CPHI Worldwide 2025,' global pharmaceutical companies showed great interest in our Microsphere technology and product portfolio. Through this event, we have concretized the strengthening of global partnerships and business expansion, and we will continue to expand our network and enhance our global competitiveness going forward."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- Experts Shocked by Record Numbers: "Just the Tip of the Iceberg" — The Identity Behind the 90% Dominating Teens [Chuiyakgukga]⑨
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
Meanwhile, Dongkook Pharmaceutical has operated an independent booth at 'CPHI Worldwide' for four consecutive years since 2022.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Mychew, but Nowhere to Be Found... Fears of a 'Pediatric Medical Crisis' as Drug Makers Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
